Can a new pill help teens regrow hair lost to alopecia?

NCT ID NCT07762443

Not yet recruiting Disease control Sponsor: Jiangsu vcare pharmaceutical technology co., LTD Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental oral medication called VC005 in adolescents aged 12 to 18 with severe alopecia areata, a condition that causes patchy or complete hair loss. The study aims to understand how the drug is processed by the body, whether it is safe, and if it shows any promise in promoting hair regrowth. Participants will take VC005 tablets for 24 weeks, with close monitoring of drug levels and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VC005 tablets
What this could lead to: If successful, this could point toward a new oral treatment option for adolescents with severe alopecia areata, potentially helping to restore hair growth.
What could go wrong: This is an early-phase, small trial (24 participants) focused on safety and dosing, so it may not prove effective. Possible side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA

Contacts and locations

Locations

The Peking University People's Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.